Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Krahl, A."'
Autor:
Rainer Krahl, Christine Günther, Scarlet Musiol, Dietger Niederwieser, Sabine Leiblein, Haifa Kathrin Al-Ali, Michael W. Deininger, Thomas Köhler, Thoralf Lange, Iris Van Hoomissen
Publikováno v:
Blood. 101:2152-2155
Imatinib induces remissions in approximately 30% of patients with chronic myeloid leukemia (CML) in myeloid blast crisis (M-BC). Because most patients eventually relapse, allogeneic stem cell transplantation (SCT) in remission offers the best chance
Autor:
Nadja Jaekel, Rayk Stengel, Martin Roskos, Rainer Krahl, Song-Yau Wang, Melanie Schneider, Susann Schulze, Haifa Kathrin Al-Ali, Karolin Hubert, Dietger Niederwieser
Publikováno v:
Blood. 126:2014-2014
Allogeneic HCT is curative in myelofibrosis (MF) with a survival (OS) advantage compared to non-JAK-inhibitor treatments in patients (pts) with Int-2/high-risk DIPSS (Kroeger et al, Blood 2015). On the other hand, data demonstrate a OS benefit of the
Autor:
Gerhard Behre, Georg Franke, Sebastian Schwind, Michael Cross, Madlen Jentzsch, Vladan Vucinic, Marius Bill, Haifa Kathrin Al-Ali, Rainer Krahl, Laura Kloss, Dietger Niederwieser, Thoralf Lange, Stephan Fricke, Wolfram Poenisch
Publikováno v:
Blood. 122:3383-3383
Allogeneic hematopoietic cell transplantation (HCT) represents a post-remission therapy offering potential cure for acute myeloid leukemia (AML) patients (pts). Reduced-Intensity Conditioning (RIC) is increasingly used in AML pts undergoing HCT ineli
Autor:
Nadja Jaekel, Cornelia Becker, Leanthe Braunert, Thoralf Lange, Rainer Krahl, Georg Franke, Dietger Niederwieser, Jeanett Edelmann, Wolfram Poenisch, Sabine Leiblein, Claudia Nehring, Haifa Kathrin Al-Ali
Publikováno v:
Blood. 118:3065-3065
Abstract 3065 Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity-conditioning (RIC) is a curative therapeutic option in elderly patients with AML. Yet, hematological relapse (HR) and non-relapse mortality (NRM) remain maj
Autor:
Hans-Heinrich Wolf, Detlev Haehling, Nadezda Basara, Haifa Kathrin Al-Ali, Christian Junghanss, Ute Kreibich, Michael Herold, Thomas M. Fischer, Norbert Grobe, Georg Maschmeyer, Rainer Krahl, Gottfried Doelken, Frank Schueler, Wolfram Poenisch, Herbert G. Sayer, Dietger Niederwieser
Publikováno v:
Blood. 114:1612-1612
Abstract 1612 Poster Board I-638 Cytogenetically normal AML (CN-AML) is a heterogeneous disease with molecular markers impacting considerably on survival. Acquired gene mutations such as the internal tandem duplication (ITD) of the FLT3 gene has been